Cargando…

Direct inhibition of STAT signaling by platinum drugs contributes to their anti-cancer activity

Platinum-based chemotherapeutics are amongst the most powerful anti-cancer drugs. Although their exact mechanism of action is not well understood, it is thought to be mediated through covalent DNA binding. We investigated the effect of platinum-based chemotherapeutics on signaling through signal tra...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hato, Stanleyson V., Figdor, Carl G., Takahashi, Susumu, Pen, Anja E., Halilovic, Altuna, Bol, Kalijn F., Vasaturo, Angela, Inoue, Yukie, de Haas, Nienke, Verweij, Dagmar, Van Herpen, Carla M.L., Kaanders, Johannes H., van Krieken, Johan H.J.M., Van Laarhoven, Hanneke W.M., Hooijer, Gerrit K.J., Punt, Cornelis J.A., Asai, Akira, de Vries, I. Jolanda M., Lesterhuis, W.J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5589592/ https://www.ncbi.nlm.nih.gov/pubmed/28903353 http://dx.doi.org/10.18632/oncotarget.17661

Ejemplares similares

T cell landscape within primary melanoma as a biomarker of survival after cancer vaccination in patients with metastatic disease
por: Vasaturo, Angela, et al.
Publicado: (2015)

STATing the importance of immune modulation by platinum chemotherapeutics
por: Hato, Stanleyson V., et al.
Publicado: (2012)

The chemotherapeutic drug oxaliplatin differentially affects blood DC function dependent on environmental cues
por: Tel, Jurjen, et al.
Publicado: (2011)

Adjuvant dendritic cell vaccination in high-risk uveal melanoma patients
por: Bol, Kalijn, et al.
Publicado: (2015)

Autologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: a prospective, randomized phase 2 trial
por: Boudewijns, Steve, et al.
Publicado: (2020)

Clinical Implications of Co-Inhibitory Molecule Expression in the Tumor Microenvironment for DC Vaccination: A Game of Stop and Go
por: Vasaturo, Angela, et al.
Publicado: (2013)

Naturally circulating dendritic cells to vaccinate cancer patients
por: Bol, Kalijn F., et al.
Publicado: (2013)

Importance of helper T-cell activation in dendritic cell-based anticancer immunotherapy
por: Schreibelt, Gerty, et al.
Publicado: (2013)

Preclinical exploration of combining plasmacytoid and myeloid dendritic cell vaccination with BRAF inhibition
por: Tel, Jurjen, et al.
Publicado: (2016)

Improving cancer immunotherapy by targeting the STATe of MDSCs
por: de Haas, Nienke, et al.
Publicado: (2016)

Programmed Death Ligand 2 in Cancer-Induced Immune Suppression
por: Rozali, Esdy N., et al.
Publicado: (2012)

Skin-derived tumor specific T cells predict clinical outcome in dendritic cell vaccination studies in both stage III and IV melanoma patients
por: Aarntzen, EHJG, et al.
Publicado: (2010)

Cisplatin inhibits frequency and suppressive activity of monocytic myeloid-derived suppressor cells in cancer patients
por: Van Wigcheren, Glenn F., et al.
Publicado: (2021)

STAT Family Protein Expression and Phosphorylation State during moDC Development Is Altered by Platinum-Based Chemotherapeutics
por: de Haas, Nienke, et al.
Publicado: (2019)

Human CD1c(+) DCs are critical cellular mediators of immune responses induced by immunogenic cell death
por: Di Blasio, Stefania, et al.
Publicado: (2016)

Immune-related Adverse Events of Dendritic Cell Vaccination Correlate With Immunologic and Clinical Outcome in Stage III and IV Melanoma Patients
por: Boudewijns, Steve, et al.
Publicado: (2016)

Paired primary and metastatic lesions of patients with ipilimumab-treated melanoma: high variation in lymphocyte infiltration and HLA-ABC expression whereas tumor mutational load is similar and correlates with clinical outcome
por: Gorris, Mark A J, et al.
Publicado: (2022)

The tumour microenvironment shapes dendritic cell plasticity in a human organotypic melanoma culture
por: Di Blasio, S., et al.
Publicado: (2020)

Ipilimumab administered to metastatic melanoma patients who progressed after dendritic cell vaccination
por: Boudewijns, Steve, et al.
Publicado: (2016)

Dendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time
por: van Willigen, Wouter W., et al.
Publicado: (2018)

Immune infiltrates impact on the prediction of prognosis and response to immunotherapy of melanoma patients
por: Vasaturo, Angela, et al.
Publicado: (2015)

A pilot study on the immunogenicity of dendritic cell vaccination during adjuvant oxaliplatin/capecitabine chemotherapy in colon cancer patients
por: Lesterhuis, W J, et al.
Publicado: (2010)

Humoral and cellular immune responses after influenza vaccination in patients with chronic fatigue syndrome
por: Prinsen, Hetty, et al.
Publicado: (2012)

Immunological responses to adjuvant vaccination with combined CD1c(+) myeloid and plasmacytoid dendritic cells in stage III melanoma patients
por: Bloemendal, Martine, et al.
Publicado: (2021)

High sensitivity of both sequencing and real-time PCR analysis of KRAS mutations in colorectal cancer tissue
por: Tol, Jolien, et al.
Publicado: (2010)

Multispectral imaging reveals the tissue distribution of tetraspanins in human lymphoid organs
por: de Winde, Charlotte M., et al.
Publicado: (2015)

Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity
por: Bol, Kalijn F., et al.
Publicado: (2016)

Phase I Dose Escalation Study with Expansion Cohort of the Addition of Nab-Paclitaxel to Capecitabine and Oxaliplatin (CapOx) as First-Line Treatment of Metastatic Esophagogastric Adenocarcinoma (ACTION Study)
por: Schokker, Sandor, et al.
Publicado: (2019)

Intranodal vaccination with mRNA-optimized dendritic cells in metastatic melanoma patients
por: Bol, Kalijn F, et al.
Publicado: (2015)

A tipping point in cancer-immune dynamics leads to divergent immunotherapy responses and hampers biomarker discovery
por: Creemers, Jeroen H A, et al.
Publicado: (2021)

Tumor‐immune landscape patterns before and after chemoradiation in resectable esophageal adenocarcinomas
por: Soeratram, Tanya TD, et al.
Publicado: (2021)

Adjuvant dendritic cell vaccination induces tumor-specific immune responses in the majority of stage III melanoma patients
por: Boudewijns, Steve, et al.
Publicado: (2016)

ASO Author Reflections: Frequent Relapses Prior to the Start of Adjuvant Therapy in Stage IIIB/C Melanoma
por: Bloemendal, Martine, et al.
Publicado: (2019)

Survival of metastatic melanoma patients after dendritic cell vaccination correlates with expression of leukocyte phosphatidylethanolamine-binding protein 1/Raf kinase inhibitory protein
por: Buschow, Sonja I., et al.
Publicado: (2017)

The dynamics of HER2 status in esophageal adenocarcinoma
por: Creemers, Aafke, et al.
Publicado: (2018)

MDA5 Detects the Double-Stranded RNA Replicative Form in Picornavirus-Infected Cells
por: Feng, Qian, et al.
Publicado: (2012)

Can we do without chemotherapy? A perspective on the combinations nivolumab-chemotherapy and nivolumab–ipilimumab in metastatic gastric and esophageal cancer
por: Derks, Sarah, et al.
Publicado: (2022)

The success of anti-PD-1 with chemotherapy for esophageal squamous cell carcinoma
por: van Laarhoven, Hanneke W.M., et al.
Publicado: (2023)

SPOTlight on GLOW
por: Derks, Sarah, et al.
Publicado: (2023)

Plasmacytoid dendritic cells of melanoma patients present exogenous proteins to CD4(+) T cells after FcγRII-mediated uptake
por: Benitez-Ribas, Daniel, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_nl4fmfjd8en428r5282lqq8dl3